A number of research firms have changed their ratings and price targets for Sangamo Therapeutics (NASDAQ: SGMO): 1/5/2021 – Sangamo Therapeutics is now covered by analysts at Stifel Nicolaus. They set a “hold” rating on the stock. 12/23/2020 – Sangamo Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating. […]
